コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 inhibitors against HIV, the culprit of AIDS (acquired immunodeficiency syndrome).
2 ed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome).
3 compromised patients with cancer or advanced acquired immunodeficiency syndrome.
4 (>/=2 symptoms), and deaths were ascribed to acquired immunodeficiency syndrome.
5 al failure, and human immunodeficiency virus/acquired immunodeficiency syndrome.
6 voirs for viral persistence in patients with acquired immunodeficiency syndrome.
7 carinii DHPS mutations in 107 patients with acquired immunodeficiency syndrome.
8 as been approved by the FDA for treatment of acquired immunodeficiency syndrome.
9 larly in the context of immunodeficiency and acquired immunodeficiency syndrome.
10 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.
11 iciency virus infection and delayed onset of acquired immunodeficiency syndrome.
12 regenerative states, immune cytopenias, and acquired immunodeficiency syndrome.
13 ts have been described only in patients with acquired immunodeficiency syndrome.
14 on opportunistic infections in patients with acquired immunodeficiency syndrome.
15 ing to the vascular injury syndromes seen in acquired immunodeficiency syndrome.
16 rus infection, particularly in patients with acquired immunodeficiency syndrome.
17 h cytomegalovirus-associated esophagitis and acquired immunodeficiency syndrome.
18 er nonmalignant CNS lesions in patients with acquired immunodeficiency syndrome.
19 ow SAAG ascites, especially in patients with acquired immunodeficiency syndrome.
20 cell counts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome.
21 ciency virus (SIV)-infected macaque model of acquired immunodeficiency syndrome.
22 using SSRI treatment adjunctively in HIV and acquired immunodeficiency syndrome.
23 in the relative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent con
24 5,321 person-years, 268 of 614 men incurred acquired immunodeficiency syndrome, 49 died, and 90 were
25 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each).
27 load after infection and 5-year incidence of acquired immunodeficiency syndrome, adjusting for (conti
28 study, baseline plasma from 619 persons with acquired immunodeficiency syndrome (AIDS) (median CD4+ l
29 fect of injection drug use on 6-year risk of acquired immunodeficiency syndrome (AIDS) after initiati
30 To investigate the validity of self-reported acquired immunodeficiency syndrome (AIDS) among women en
31 ne their associations with incident clinical acquired immunodeficiency syndrome (AIDS) and CD4+ T cel
32 ) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococc
33 iciency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed b
34 gnificant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortali
35 T) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased
36 pontine myelinolysis), infections [malaria, acquired immunodeficiency syndrome (AIDS) and infection
37 es suggest a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium d
40 Encephalitis and dementia associated with acquired immunodeficiency syndrome (AIDS) are characteri
41 ections of the biliary tree in patients with acquired immunodeficiency syndrome (AIDS) are well known
42 return visit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment.
43 ed 13 years or older who were diagnosed with acquired immunodeficiency syndrome (AIDS) between Januar
45 mimic a clinical trial to assess the risk of acquired immunodeficiency syndrome (AIDS) by timing of t
46 quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the Un
47 ods for estimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attribut
48 lor represent an increasing proportion of US acquired immunodeficiency syndrome (AIDS) cases, few res
49 cterized for certain biliary diseases, e.g., acquired immunodeficiency syndrome (AIDS) cholangiopathy
50 Biliary cryptosporidiosis is associated with acquired immunodeficiency syndrome (AIDS) cholangiopathy
51 ession on CD8(+) T lymphocytes may relate to acquired immunodeficiency syndrome (AIDS) clinical progr
52 ficiency virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the
55 (HIV)-infected brain in relationship to the acquired immunodeficiency syndrome (AIDS) dementia compl
56 have been implicated in the pathogenesis of acquired immunodeficiency syndrome (AIDS) dementia compl
58 human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has g
59 se to the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is th
62 (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but
64 y to grant the request of a patient with the acquired immunodeficiency syndrome (AIDS) for assistance
65 networks in predicting rapid progression to acquired immunodeficiency syndrome (AIDS) for patients w
66 genes into both T cells and macrophages for acquired immunodeficiency syndrome (AIDS) gene therapy.
68 ndidate genes for stem cell gene therapy for acquired immunodeficiency syndrome (AIDS) has been limit
70 ons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required
71 r and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-y
72 eficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, eff
73 SIVsm from sooty mangabeys, are the cause of acquired immunodeficiency syndrome (AIDS) in humans.
74 virus type 1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS) in humans.
75 ently have focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, sever
76 mmunodeficiency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan
77 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal
78 's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS w
79 iruses, however, SIVs do not generally cause acquired immunodeficiency syndrome (AIDS) in their natur
80 activation is a key factor in progression to acquired immunodeficiency syndrome (AIDS) in untreated H
82 l leukoencephalopathy (PML) complicating the acquired immunodeficiency syndrome (AIDS) is typically i
84 uals with a high viral set point progress to acquired immunodeficiency syndrome (AIDS) more rapidly t
86 lative risk (RR) for clinical progression to acquired immunodeficiency syndrome (AIDS) of 1.66 (95% c
87 idemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for
88 gosity of class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among pa
89 c millimeter or until the development of the acquired immunodeficiency syndrome (AIDS) or another con
90 hly active antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,
91 iretroviral therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while
92 ve antiretroviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the
93 re urgently needed to curb the growth of the acquired immunodeficiency syndrome (AIDS) pandemic and u
96 V-infected populations compared with similar acquired immunodeficiency syndrome (AIDS) patients in th
97 This study reports the surgical outcomes of acquired immunodeficiency syndrome (AIDS) patients with
99 entify cancers that occur at higher rates in acquired immunodeficiency syndrome (AIDS) patients, the
100 es persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients.
101 tivation and drives systemic inflammation in acquired immunodeficiency syndrome (AIDS) patients.
102 fection in a new host is a critical goal for acquired immunodeficiency syndrome (AIDS) research.
103 tion analysis of five cohorts of people with acquired immunodeficiency syndrome (AIDS) revealed that
105 ococcal disease incidence among persons with acquired immunodeficiency syndrome (AIDS) since the intr
106 reduced in alveolar macrophages and PMN from acquired immunodeficiency syndrome (AIDS) subjects, we i
107 The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 1
108 age is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility
109 iciency virus (HIV) among cases who obtained acquired immunodeficiency syndrome (AIDS) through hetero
110 nctively associated with communication about acquired immunodeficiency syndrome (AIDS) through social
111 esign, the authors compared 1,642 women with acquired immunodeficiency syndrome (AIDS) to 8,443 uninf
112 ted from monkeys with acute SIV infection or acquired immunodeficiency syndrome (AIDS) underwent norm
113 impact of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) versus other l
114 ed States-based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped
115 megalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiv
116 gous state, SDF1-3'A/3'A delays the onset of acquired immunodeficiency syndrome (AIDS), according to
117 affects about 4 percent of patients with the acquired immunodeficiency syndrome (AIDS), and survival
118 se to cryptosporidiosis in patients with the acquired immunodeficiency syndrome (AIDS), and went on t
119 tomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does n
120 redicts the likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relat
121 ere followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the
122 ncy virus type 1 (HIV-1), the cause of human acquired immunodeficiency syndrome (AIDS), is a zoonotic
123 ciency virus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears th
124 udy was to measure, as a model of wasting in acquired immunodeficiency syndrome (AIDS), longitudinal
125 eases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defi
127 reduced prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the
128 inment of deaths among people diagnosed with acquired immunodeficiency syndrome (AIDS), the authors d
129 ctives on human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis
130 and immune activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated
131 ly antiretroviral therapy, which can prevent acquired immunodeficiency syndrome (AIDS)-associated eve
133 virus (SIV)-infected macaques as a model of acquired immunodeficiency syndrome (AIDS)-associated P.
135 asures were death, the occurrence of a first acquired immunodeficiency syndrome (AIDS)-defining condi
136 carinii pneumonia was the initial (and only) acquired immunodeficiency syndrome (AIDS)-defining diagn
137 re divided by disease severity defined as an acquired immunodeficiency syndrome (AIDS)-defining event
139 definition of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining event
140 ion, which was defined as all occurrences of acquired immunodeficiency syndrome (AIDS)-defining event
141 e antiretroviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illne
142 did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illne
143 nemia was 36.9% for persons with one or more acquired immunodeficiency syndrome (AIDS)-defining oppor
144 o identify CD4(+) levels associated with the acquired immunodeficiency syndrome (AIDS)-free time equi
147 from eight HCV-infected patients who died of acquired immunodeficiency syndrome (AIDS)-related compli
148 venues for investigating the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related cytope
149 To determine whether microbiologic cure of acquired immunodeficiency syndrome (AIDS)-related dissem
150 and to determine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experi
151 munodeficiency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnes
152 e 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi
154 osing event in the early pathogenesis of the acquired immunodeficiency syndrome (AIDS)-related lympho
155 ffect of time-varying incident TB on time to acquired immunodeficiency syndrome (AIDS)-related mortal
156 in Kaposi's sarcoma (KS), as well as in some acquired immunodeficiency syndrome (AIDS)-related non-Ho
157 emonstrated that prior to the development of acquired immunodeficiency syndrome (AIDS)-related pulmon
158 mic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I
195 ders, and infectious diseases (excluding the acquired immunodeficiency syndrome [AIDS]), many of whic
196 2382 at low risk, 698 at high risk, 242 with acquired immunodeficiency syndrome [AIDS], and 248 "nons
197 interferon (rIFN)- gamma 1b in patients with acquired immunodeficiency syndrome and acute cryptococca
198 from culture isolates from 87 patients with acquired immunodeficiency syndrome and CMV retinitis who
199 rnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis.
200 they had an increased risk of progression to acquired immunodeficiency syndrome and death, a relation
201 sis is classically reported in patients with acquired immunodeficiency syndrome and emerged as a caus
202 regular alcohol consumption (one of whom had acquired immunodeficiency syndrome and hepatitis B), one
203 and clinical parameters among patients with acquired immunodeficiency syndrome and histoplasmosis in
204 ts with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious
205 rden created by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious
206 rates of incarceration and reported cases of acquired immunodeficiency syndrome and syphilis were wea
207 to neonatal infection, transplantation, and acquired immunodeficiency syndrome-associated CMV diseas
208 iants, 3 primary cutaneous (PC) forms, and 3 acquired immunodeficiency syndrome-associated forms.
210 reducing the disease burden in patients with acquired immunodeficiency syndrome-associated tuberculos
211 ognitive disorders, we examined persons with acquired immunodeficiency syndrome before their death an
213 eme Court's first case involving HIV and the acquired immunodeficiency syndrome, Bragdon v Abbott, ad
216 to develop immunotherapeutic strategies for acquired immunodeficiency syndrome capable of activating
217 he basic package of services provided by HIV/acquired immunodeficiency syndrome care and treatment pr
218 In patients with sclerosing cholangitis and acquired immunodeficiency syndrome cholangiopathy, MRCP
219 s were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group
220 men who were participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-
221 en-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious ad
222 00 x 10(6)/L and 549 x 10(6)/L without prior acquired immunodeficiency syndrome-defining conditions r
223 ficantly higher for patients without a prior acquired immunodeficiency syndrome-defining illness and
224 tion, whereas patients who developed another acquired immunodeficiency syndrome-defining illness did
225 s were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or d
226 nts with Medicaid, and patients with a prior acquired immunodeficiency syndrome-defining illness were
227 infection and CIN, and cervical cancer is an acquired immunodeficiency syndrome-defining illness.
228 r, and 65 percent of the patients had had an acquired immunodeficiency syndrome-defining illness.
229 ive multifocal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness.
230 es brain function and presents clinically as acquired immunodeficiency syndrome dementia complex (ADC
231 vanced immunodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had
232 tors for NTS, including autoimmune diseases, acquired immunodeficiency syndrome, diabetes, cirrhosis,
235 ntigen genetic association with HIV-1 and/or acquired immunodeficiency syndrome disease progression i
238 ted from 2 ALIVE scientists and an expert in acquired immunodeficiency syndrome epidemiology about th
239 r patients attending a county outpatient HIV/acquired immunodeficiency syndrome facility were referre
240 1984-2008, regarding estimation of long-term acquired immunodeficiency syndrome-free survival to demo
241 ciency virus (HIV)-infected subjects without acquired immunodeficiency syndrome have a high frequency
242 Although the incidence of and mortality from acquired immunodeficiency syndrome have declined recentl
243 orbid human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) (OR = 4.27
244 h has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and t
246 ch as diabetes, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), arthritis
247 illimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defini
248 t the LP-BM5 murine leukemia virus causes an acquired immunodeficiency syndrome in C57BL/6 mice (MAID
249 etermine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals alread
250 rculosis is often the first manifestation of acquired immunodeficiency syndrome in patients infected
251 fection causes an AIDS-like syndrome--murine acquired immunodeficiency syndrome--in C57B1/6 mice and
253 type 1 reduces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminat
254 cted injection drug users recruited into the Acquired Immunodeficiency Syndrome Link to Intravenous E
256 man immunodeficiency virus infection and the acquired immunodeficiency syndrome, medical malpractice,
258 to initiate therapy prior to progression to acquired immunodeficiency syndrome or death by both meas
259 ts of dropout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing us
260 ly active antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors
261 active antiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 drop
262 r patients with human immunodeficiency virus/acquired immunodeficiency syndrome or substance abuse (f
263 0, CI 0.28-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.7
265 anciclovir has become increasingly common in acquired immunodeficiency syndrome patients but has only
266 the spinal cord dorsal horn (SDH) from HIV-1/acquired immunodeficiency syndrome patients who develope
267 g patients with human immunodeficiency virus/acquired immunodeficiency syndrome, patients receiving t
268 revious serologic diagnosis of HIV, from the acquired immunodeficiency syndrome program of the Health
269 ococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Afr
270 npatient medical records to document HIV and acquired immunodeficiency syndrome-related diagnoses.
271 imately 25% of patients with newly diagnosed acquired immunodeficiency syndrome-related lymphoma (ARL
272 ived a heterologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from
275 was used to evaluate the effect of HAART on acquired immunodeficiency syndrome-related mortality, ad
277 n human immunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis
279 ed with an immunodeficiency syndrome (simian acquired immunodeficiency syndrome [SAIDS]) caused by a
281 subtyping is not integrated into routine HIV/acquired immunodeficiency syndrome surveillance in the U
282 virus induces a complex disease featuring an acquired immunodeficiency syndrome termed murine AIDS (M
283 aracterized by slower disease progression to acquired immunodeficiency syndrome than results from HIV
285 rvum is a major problem in patients with the acquired immunodeficiency syndrome, the specific microbi
287 the worldwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and ma
289 tions of measles in the setting of a chronic acquired immunodeficiency syndrome virus infection.
290 eys were used to clarify the distribution of acquired immunodeficiency syndrome virus-specific cytoto
292 age of > 10% and a positive association with acquired immunodeficiency syndrome were borderline signi
293 R, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to r
294 eukemia, lymphoma, severe liver disease, and acquired immunodeficiency syndrome were rarely identifie
295 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the
296 ination of brain tissue from 2 patients with acquired immunodeficiency syndrome who had CMV encephali
297 chieving immune restoration in patients with acquired immunodeficiency syndrome who have incomplete r
298 s, malaria, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant res
300 st a close friend or intimate partner to the acquired immunodeficiency syndrome within the prior 6 mo
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。